Denali Therapeutics (DNLI) FY2021 results: revenue $49 million, down 85.5% on the year
Denali Therapeutics Inc. (DNLI) reported revenue of $49 million for fiscal 2021, the year ended 31 December 2021, down 85.5% on the year before. Net income was -$291 million, and diluted earnings per share $-2.39. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2022.
Revenue
$49 million
-85.5% on the year
FY2016FY2021
Operating margin
-607.8%
18.7% a year earlier
FY2016FY2021
Net income
-$291 million
FY2016FY2021
Diluted EPS
-$2.39
FY2016FY2021
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
-211
416
-152
Capital expenditure
8.5
3.1
17.9
+174.6%
Free cash flow
-220
413
-169
Free cash flow margin
-451.9%
123.1%
-635.3%
Cash from investing
-21.6
-623
148
Cash from financing
19.3
635
6.2
-97.0%
Depreciation and amortisation
8.6
8.5
8.0
+0.7%
Share-based compensation
85.2
50.4
38.4
+69.3%
Diluted shares, weighted
122m
113m
96m
+7.8%
Shares outstanding at period end
122m
121m
96m
+1.5%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
962
1,151
395
-16.4%
Debt
0.0
0.0
0.0
Operating lease liabilities
58.6
64.2
68.9
-8.8%
Other liabilities
383
390
89.5
-1.6%
Total liabilities and equity
1,404
1,604
553
-12.5%
Fixed assets
38.9
40.8
46.7
-4.8%
Investments
997
995
376
+0.2%
Cash and equivalents
293
507
79.4
-42.1%
Receivables
n/a
8.6
n/a
Other assets
74.4
52.4
51.3
+41.9%
Total assets
1,404
1,604
553
-12.5%
10-K for the year ended 31 December 2021, filed 28 February 2022: the filing.